Skip to main content

Table 6 Hypoglycemia Outcomes (ITT population)

From: Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial

 

Episodes per patient year

Hypoglycemia rates

Hypoglycemia

Insulin Glargine mean (95 %CI)

NPH insulin mean (95 %CI)

Insulin Glargine % (95 %CI)

NPH insulin % (95 %CI)

p-value*

(N = 327)

(N = 323)

(N = 327)

(N = 323)

Total exposure time in yearsa

144.8

144.5

   

Threshold <3.1 mmol/L

     

Overall hypoglycemia

0.87 (0.73-1.04)

0.81 (0.67-0.97)

17.7 (13.8-22.3)

15.8 (12.0-20.2)

0.2492

Daytime hypoglycemia

0.59 (0.48-0.73)

0.49 (0.38-0.62)

12.8 (9.4-17.0)

12.1 (8.7-16.1)

0.4751

Nocturnal hypoglycemia

0.28 (0.20-0.38)

0.32 (0.23-0.42)

6.4 (4.0-9.6)

7.4 (4.8-10.9)

0.7150

Threshold <3.9 mmol/L

     

Overall hypoglycemia

1.43 (1.24-1.64)

1.46 (1.27-1.67)

25.1 (20.5-30.1)

23.2 (18.7-28.2)

0.2922

Daytime hypoglycemia

1.02 (0.86-1.20)

0.91 (0.76-1.08)

20.5 (16.2-25.3)

18.3 (14.2-22.9)

0.2253

Nocturnal hypoglycemia

0.41 (0.31-0.53)

0.55 (0.44-0.69)

7.6 (5.0-11-1)

10.8 (7.7-14.7)

0.1699

Severe hypoglycemiab

0.00 (NE-0.03)

0.01 (0.00-0.05)

0.0 (0.0-1.1)

0.6 (0.1-2.2)

NA

  1. Legend: *McNemar test applied; bone daytime event for each type of insulin; acalculated by adding the exposure time of each patient to each type of insulin